Bausch Lomb — Key Risks
BHC Controls 88% of Shares, Limiting Shareholder Influence Until a Separation is Completed
Bausch Health Companies (BHC) currently owns approximately 88% of Bausch + Lomb's outstanding shares, meaning BHC can unilaterally decide almost every important corporate matter — acquisitions, dividends, management changes, and strategic direction. As a retail investor, your vote essentially carries no weight while this structure remains in place. BHC's own financial troubles, shareholder activism, and even potential debt defaults could spill over and harm Bausch + Lomb's credit ratings and operations.
The Full Separation from BHC May Never Happen, or Could Happen on Worse Terms
The planned "Distribution" (a full spin-off from BHC) has no guaranteed completion date and requires multiple conditions — including BHC hitting certain debt leverage targets, receiving tax rulings from both the IRS and Canada Revenue Agency, and obtaining shareholder and court approvals. BHC can abandon the plan entirely at its sole discretion. If separation is delayed or restructured, investors lose the anticipated benefit of Bausch + Lomb operating as a truly independent company.
The Company Carries Over $5 Billion in Debt, Mostly at Variable Rates
As of December 31, 2025, Bausch + Lomb had $3,695 million in variable-rate debt and $1,412 million in fixed-rate debt. Variable-rate debt means interest costs rise automatically when rates increase. The debt agreements also restrict the company's ability to make acquisitions, pay dividends, or take on more financing — limiting strategic flexibility precisely when opportunities or crises may arise.
Key Products Rely on Single Suppliers With No Backup
Several of Bausch + Lomb's most important products — including MIEBO, XIIDRA, Lumify, Vyzulta, and PureVision contact lenses — depend on a single manufacturer or a single source for their active ingredient. If any one of those suppliers fails, faces a regulatory shutdown, or raises prices, there is no quick alternative. Switching sources for a pharmaceutical ingredient often requires fresh regulatory approval, which takes significant time and expense.
Patents Are Expiring and Generic Competition Is a Constant Threat
A meaningful portion of the product portfolio either lacks strong patent protection or has patents expiring soon. Once a patent lapses, generic competitors can enter the market and typically capture a large share of sales very rapidly, often at prices far below the branded product. The filing specifically notes that some products already face competition despite having active patents.
Product Pipeline Success Is Uncertain and Expensive
Developing new drugs and medical devices is costly, time-consuming, and often fails. Clinical trials can run for years with no guarantee of FDA or international approval. Even products that look promising early may fail in later-stage trials or receive approval with restrictive labeling that limits commercial value. A thin or underperforming pipeline puts long-term revenue growth at risk.
Pricing Power Is Being Squeezed by Regulation and Insurers
The Inflation Reduction Act penalizes drug makers whose prices rise faster than inflation for Medicare-covered products, and the government is beginning to directly negotiate prices for high-cost drugs. A 2025 executive order on "most-favored nation" drug pricing could further compress margins on branded pharmaceuticals. Combined with insurers pushing patients toward cheaper generic alternatives, Bausch + Lomb's ability to grow revenue through pricing is increasingly constrained.